|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Keloid
|
0.300 |
Biomarker
|
disease |
CTD_human |
Various classes of proteins were found either to be present or to be upregulated in keloid tissue: (i) inflammatory/differentiated keratinocyte markers: S100 proteins, peroxiredoxin I; (ii) wound healing proteins: gelsolin-like capping protein; (iii) fibrogenetic proteins: mast cell β-tryptase, macrophage migration inhibitory factor (MIF); (iv) antifibrotic proteins: asporin; (v) tumour suppressor proteins: stratifin, galectin-1, maspin; and (vi) antiangiogenic proteins: pigment epithelium-derived factor.
|
20128793 |
2010 |
|
Adenocarcinoma of lung (disorder)
|
0.300 |
Biomarker
|
disease |
CTD_human |
Comparative proteome analysis of human adenocarcinoma.
|
19381893 |
2010 |
|
Leukemia, Myelocytic, Acute
|
0.300 |
Biomarker
|
disease |
CTD_human |
Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
|
18206229 |
2008 |
|
Acute Myeloid Leukemia, M1
|
0.300 |
Biomarker
|
disease |
CTD_human |
Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
|
18206229 |
2008 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.300 |
Biomarker
|
disease |
CTD_human |
Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
|
18206229 |
2008 |
|
Renal Cell Carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Differential protein profiling in renal-cell carcinoma.
|
15108329 |
2004 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Differential protein profiling in renal-cell carcinoma.
|
15108329 |
2004 |
|
Chromophobe Renal Cell Carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Differential protein profiling in renal-cell carcinoma.
|
15108329 |
2004 |
|
Sarcomatoid Renal Cell Carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Differential protein profiling in renal-cell carcinoma.
|
15108329 |
2004 |
|
Collecting Duct Carcinoma of the Kidney
|
0.300 |
Biomarker
|
disease |
CTD_human |
Differential protein profiling in renal-cell carcinoma.
|
15108329 |
2004 |
|
Papillary Renal Cell Carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Differential protein profiling in renal-cell carcinoma.
|
15108329 |
2004 |
|
Atypical Hemolytic Uremic Syndrome
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Atypical hemolytic-uremic syndrome: recurrent phenotypic expression of a patient with MCP gene mutation combined with risk haplotypes.
|
30676336 |
2019 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
To improve the therapy efficiency as a PTT agent, the MCP NPs are further modified with functional polyethylene glycol (PEG) and thiol terminal cyclic arginine-glycine-aspartic acid peptide, respectively: the first one is to increase the stability, biocompatibility, and blood circulation time of MCP NPs in vivo; the second one is to increase the tumor accumulation of MCP-PEG NPs and improve their therapeutic efficiency as photothermal agent.
|
29938191 |
2018 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Downregulated DEGs included TFs, such as the proto‑oncogene SPI1, pre‑B‑cell leukemia homeobox 3 (PBX3) and lymphoid enhancer‑binding factor 1 (LEF1), as well as tumor suppressors (TSs), such as capping actin protein, gelsolin like (CAPG) and tumor protein p53‑inducible nuclear protein 1 (TP53INP1).
|
28791367 |
2017 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
The combination of CTNB1, XPO2, and CAPG achieved 95% sensitivity and 96% specificity for the discrimination of these subtypes.<b>Conclusions:</b> We developed two uterine aspirate-based signatures to diagnose EC and classify tumors in the most prevalent histologic subtypes.
|
28790116 |
2017 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
The IHC results demonstrated that CapG was relatively highly expressed in CRC tissue compared with non-tumor tissue (P<0.001), and that the expression of CapG was significantly associated with the tumor site, differentiation, lymph node metastasis and clinical stage (P=0.021, P=0.036, P=0.012 and P=0.009, respectively).
|
29113183 |
2017 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
We found that macrophage-capping protein (CapG) was up-regulated in the tumor tissues of patients with LNM, whereas it showed an equivalent expression level between nontumor and tumor tissues of patients without LNM.
|
23782053 |
2013 |
|
Atypical Hemolytic Uremic Syndrome
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
In summary, these data suggest that genotyping for the risk haplotypes in CFH and MCP may help predict the risk of developing aHUS in unaffected carriers of mutations.
|
23431077 |
2013 |
|
Atypical Hemolytic Uremic Syndrome
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
We presented the second reported case of aHUS associated with a heterozygous c.191G > T mutation in exon 2 of MCP who responded rapidly to plasma exchange.
|
24005975 |
2013 |
|
Atypical Hemolytic Uremic Syndrome
|
0.070 |
Biomarker
|
disease |
BEFREE |
Previously, we identified pathogenic variations in genes encoding complement regulators (CFH, CFI and MCP) in our aHUS cohort.
|
22622361 |
2012 |
|
Atypical Hemolytic Uremic Syndrome
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Surprisingly, 4 patients had mutations only in MCP, without mutations in any of the other genes that cause aHUS.
|
21706448 |
2012 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
One hundred six of 224 (47%) CNS tumors were positive for HHV-6 U57 Major Capsid Protein (MCP) gene by ISH compared to 0/25 non tumor control brain (P = 0.001).
|
19424665 |
2009 |
|
Atypical Hemolytic Uremic Syndrome
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Successful renal transplantation in a patient with atypical hemolytic uremic syndrome carrying mutations in both factor I and MCP.
|
19459807 |
2009 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
We found that CLU and ITGB3 were more expressed in tumors from survivors and PRAME and CAPG were more expressed in tumors from deceased patients.
|
18709641 |
2008 |